If Kevetrin works well against many cancers, then yes, it will eclipse Brilacidin ABSSSI easily.
Yes, I believe the B P3 interim results will be in and will be submitted for review under Fast Track before we get any K P2 results. B will be a fast trial as it is an antibiotic for a very common condition. Even without Fast Track it will likely be complete before any K P2 trial.
The thing to keep in mind is that we have a pretty good hunch that K have a shot against Ovarian but the real money question is how broad will the usage be in other cancers. It could be the biggest cancer drug of all time or it could merely have specialized uses.
My point was that we will likely have B, P, B-OM approvals/partnerships before Kevetrin is approved for any major indication. It's feasible that B and P could have approval/partnerships this year. More likely 2017, but the possibility is there.
Also, don't forget about the whale that is B-UP.
News 
Market Data 
Discover 
